帕博利珠单抗联合白蛋白紫杉醇与卡培他滨方案治疗进展期胃癌患者的疗效评估

doi:10.3760/cma.j.issn.1007-1245.2024.09.006

摘要/Abstract

摘要：

目的　探讨帕博利珠单抗联合白蛋白紫杉醇与卡培他滨方案在治疗进展期胃癌中的疗效。方法　选取2019年10月至2022年9月西安交通大学附属红会医院收治的122例进展期胃癌患者进行随机对照试验，按照随机数字表法分为两组，各61例。对照组男48例、女13例，年龄（62.45±5.47）岁，接受卡培他滨方案联合白蛋白紫杉醇治疗；观察组男47例、女14例，年龄（63.14±5.65）岁，在对照组基础上增加帕博利珠单抗治疗。每3周为1个疗程，治疗2个疗程。对比两组患者临床疗效、治疗前后血清肿瘤标志物［糖类抗原724（CA-724）、糖类抗原199（CA-199）、血管内皮生长因子（VEGF）、肿瘤坏死因子-α（TNF-α）］、不良反应及预后情况。采用t检验、χ²检验。结果　观察组总有效率为68.85%（42/61），高于对照组的47.54%（29/61），差异有统计学意义（χ²=5.509，P=0.019）。治疗前，两组患者CA-724、CA-199、VEGF、TNF-α水平比较，差异均无统计学意义（均P>0.05）；治疗6周后，观察组CA-724、CA-199、VEGF、TNF-α水平均低于对照组［（17.56±2.22）μg/L比（22.53±2.49）μg/L、（21.56±3.21）U/ml比（27.52±3.44）U/ml、（271.64±21.22）ng/L比（281.33±24.15）ng/L、（15.08±2.53）μg/L比（19.54±3.68）μg/L］，差异均有统计学意义（t=11.636、9.893、2.354、7.800，均P<0.05）。观察组治疗期间Ⅲ～Ⅳ级血小板减少事件发生率为4.92%（3/61），低于对照组的18.03%（11/61），差异有统计学意义（χ²=5.164，P=0.023）；两组患者粒细胞减少、腹泻、甲状腺功能减退发生率比较，差异均无统计学意义（均P>0.05）。随访1年，观察组生存率为95.08%（58/61），高于对照组的83.61%（51/61），差异有统计学意义（χ²=4.218，P=0.039）。结论　帕博利珠单抗联合白蛋白紫杉醇治疗进展期胃癌的疗效良好，可有效降低血清肿瘤标志物水平。

关键词:

进展期胃癌, 帕博利珠单抗, 白蛋白紫杉醇, 卡培他滨, 疗效, 血清肿瘤标志物

Abstract:

Objective　To explore the efficacy of pembrolizumab combined with albumin-bound paclitaxel in the treatment of patients with advanced gastric cancer. Methods　From October 2019 to October 2022, 122 patients with advanced gastric cancer treated at Hong hui Hospital, Xi'an Jiaotong University were selected for the randomized controlled trial, and were divided into an observation group and a control group by the random number table method, with 61 cases in each group. There were 47 males and 14 females in the observation group who were (63.14±5.65) years old. There were 48 males and 13 females in the control group who were (62.45±5.47) years old. The control group were treated with the capecitabine regimen and albumin-bound paclitaxel; in addition, the observation group took pembrolizumab. The clinical efficacies, serum levels of tumor markers [carbohydrate antigen-724 (CA-724), carbohydrate antigen-199 (CA-199), vascular endothelial growth factor (VEGF), and tumor necrosis factor-α (TNF-α)] before and after the treatment, and adverse reactions were compared between the groups using t and χ² tests. Results　The total effective rate in the observation group was higher than that in the control group [68.85% (42/61) vs. 47.54% (29/61)], with a statistical difference (χ²=5.509, P=0.019). Before the treatment, there were no statistical differences in the levels of CA-724, CA-199, VEGF, and TNF-α between the two groups (all P>0.05). After the treatment, the levels of CA-724, CA-199, VEGF, and TNF-α in the observation group were lower than those in the control group [(17.56±2.22) μg/L vs. (22.53±2.49) μg/L, (21.56±3.21) U/ml vs. (27.52±3.44) U/ml, (271.64±21.22) ng/L vs. (281.33±24.15) ng/L, and (15.08±2.53) μg/L vs. (19.54±3.68) μg/L], with statistical differences (t=11.636, 9.893, 2.354, and 7.800; all P<0.05). The incidence of grade Ⅲ-Ⅳ thrombocytopenia in the observation group was lower than that in the control group [4.92% (3/61) vs. 18.03% (11/61)], with a statistical difference (χ²=5.164, P=0.023). There were no statistical differences in the incidences of neutropenia, diarrhea, and hypothyroidism between the two groups (all P>0.05). After one-year follow-up, the survival rate in the observation group was higher than that in the control group [95.08% (58/61) vs. 83.61% (51/61)] (χ²=4.218, P=0.039). Conclusion　The combination of pembrolizumab and albumin-bound paclitaxel for patients with advanced gastric cancer is effective, and can significantly reduce their levels of serum tumor markers.

Key words:

Advanced gastric cancer, Pembrolizumab, Albumin-bound paclitaxel, Capecitabine, Efficacy, Serum tumor markers

王文斌郭小花郑兆华郭曼孙力.

帕博利珠单抗联合白蛋白紫杉醇与卡培他滨方案治疗进展期胃癌患者的疗效评估 [J]. 国际医药卫生导报, 2024, 30(9): 1430-1434.

Wang Wenbin, Guo Xiaohua, Zheng Zhaohua, Guo Man, Sun Li.

Efficacy of pembrolizumab combined with albumin-bound paclitaxel and capecitabine in treatment of patients with advanced gastric cancer [J]. International Medicine and Health Guidance News, 2024, 30(9): 1430-1434.

参考文献

[1] 康殷楠,陈顺,解有成,等. 抗体药物偶联物在HER2阳性晚期胃癌中的应用进展和展望[J]. 中国癌症杂志,2023,33(8):790-800.DOI:10.19401/j.cnki.1007-3639.2023.08.008.
[2] 朱军,黄美金,陈宏. 进展期胃癌免疫治疗的研究进展[J]. 癌症进展,2022,20(12):1189-1193.DOI:10.11877/j.issn.1672-1535.2022.20.12.01.
[3] 郭欣,边识博,彭正,等. 进展期胃癌根治术中脾门淋巴结清扫的手术方式选择及转移预警评价:一项前瞻性单中心随机对照研究[J]. 中华胃肠外科杂志,2020,23(2):144-151.DOI:10.3760/cma.j.issn.1671-0274.2020.02.009.
[4] Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial[J].JAMA Oncol,2020,6(10):1571-1580.DOI:10.1001/jamaoncol.2020.3370.
[5] Ishigami H, Fujiwara Y, Fukushima R, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial[J].J Clin Oncol,2018,36(19):1922-1929.DOI:10.1200/JCO.2018.77.8613.
[6] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009,45(2):228-247.DOI:10.1016/j.ejca.2008.10.026.
[7] Dueck AC, Mendoza TR, Mitchell SA, et al. Validity and reliability of the US national cancer institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)[J].JAMA Oncol,2015,1(8):1051-1059.DOI:10.1001/jamaoncol.2015.2639.
[8] 袁梦,汪盛,杨春艳,等. 奥沙利铂与氟尿嘧啶类药物基因多态性对晚期胃肠癌患者疗效和不良反应影响的真实世界研究[J]. 中国医院药学杂志,2023,43(17):1949-1954.DOI:10.13286/j.1001-5213.2023.17.11.
[9] 高毓,夏楠,周福祥. PRODIGY:多西他赛、奥沙利铂+S-1新辅助化疗联合手术及S-1辅助化疗对比手术及S-1辅助化疗治疗可切除局晚期胃癌的Ⅲ期研究[J]. 中华医学杂志,2022,102(12):857.DOI:10.3760/cma.j.issn.0376-2491. 2022.12.101.
[10] 卢娟,杜思成,赵传华,等. 晚期胃癌—线免疫检查点抑制剂联合化疗预后因素及对二线化疗的影响[J]. 中国肿瘤临床,2023,50(1):22-29.DOI:10.12354/j.issn.1000-8179. 2023.20221094.
[11] 秦玉翠,夏芸. 叉头框蛋白P3阳性调节性T细胞和程序性死亡受体1/程序性死亡受体配体1通路在早期胃癌中的表达及相关性分析[J]. 中国医药导报,2023,20(23):34-37.DOI:10.20047/j.issn1673-7210.2023.23.06.
[12] 季德林,冯克海,谢韬. 卡瑞利珠单抗+白蛋白紫杉醇+奈达铂/顺铂治疗老年晚期食管癌的临床疗效观察[J]. 中国现代医学杂志,2022,32(23):6-10.DOI:10.3969/j.issn. 1005-8982.2022.23.002.
[13] 张瑾,刘艳屏. 贝伐珠单抗联合紫杉醇脂质体对老年晚期胃癌患者血清CEA、CA199、MMP-2及MMP-9水平的影响[J]. 中国老年学杂志,2018,38(5):1108-1110.DOI:10.3969/j.issn.1005-9202.2018.05.032.
[14] 王俊松,吕秀鹏. 卡培他滨、奥沙利铂联合帕博利珠单抗对进展期胃癌的疗效及安全性[J]. 实用药物与临床,2022,25(3):217-220.DOI:10.14053/j.cnki.ppcr.202203006.
[15] 陈昱倩,孙蓉,吴昊. 血清miR-200C单独或联合CEA、 CA-199和CA-724检测对胃癌患者的诊断价值[J]. 临床和实验医学杂志,2021,20(22):2399-2402.DOI:10.3969/j.issn.1671-4695.2021.22.014.
[16] 王青,杨觅,陈敏敏,等. 人表皮生长因子2、血管内皮生长因子和生长抑素受体在中老年进展期胃癌组织中的表达及意义[J]. 国际老年医学杂志,2022,43(3):299-303.DOI:10.3969/j.issn.1674-7593.2022.03.011.
[17] 董志强,刘美荣,任秀梅. IL-1β、TNF-α联合IL-6对胃癌的诊断价值[J]. 实用癌症杂志,2020,35(1):28-30.DOI:10.3969/j.issn.1001-5930.2020.01.008.
[18] Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial[J].Lancet,2018,392(10142):123-133.DOI:10.1016/S0140-6736(18)31257-1.
[19] Rha SY, Oh DY, Yañez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial[J].Lancet Oncol,2023,24(11):1181-1195.DOI:10.1016/S1470-2045(23)00515-6.
[20] 李玲.HER-2联合血清肿瘤标志物检测在胃癌诊断中的临床价值[J].广州医药,2023,54(7):30-34.DOI:10.3969/j.issn.1000-8535.2023.07.005.